0 3 The the DT 4 12 NF-kappa NF-kappa NNP 13 14 B B NNP 15 24 inhibitor inhibitor NN 24 25 , , , 26 35 tepoxalin tepoxalin NN 35 36 , , , 37 47 suppresses suppress VBZ 48 55 surface surface NN 56 66 expression expression NN 67 69 of of IN 70 73 the the DT 74 78 cell cell NN 79 87 adhesion adhesion NN 88 97 molecules molecule NNS 98 103 CD62E CD62E NNP 103 104 , , , 105 115 CD11b/CD18 cd11b/cd18 NN 116 119 and and CC 120 125 CD106 CD106 NNP 125 126 . . . 128 137 Tepoxalin Tepoxalin NNP 137 138 , , , 139 140 a a DT 141 145 dual dual JJ 146 152 enzyme enzyme NN 153 162 inhibitor inhibitor NN 163 165 of of IN 166 180 cyclooxygenase cyclooxygenase NN 181 184 and and CC 185 199 5-lipoxygenase 5-lipoxygenase NN 200 203 has have VBZ 204 208 been be VBN 209 214 shown show VBN 215 217 to to TO 218 225 inhibit inhibit VB 226 232 T-cell t-cell NN 233 243 activation activation NN 243 244 . . . 245 248 Its its PRP$ 249 266 immunosuppressive immunosuppressive JJ 267 275 property property NN 276 278 is be VBZ 279 287 distinct distinct JJ 288 292 from from IN 293 304 cyclosporin cyclosporin NN 305 312 because because IN 313 317 only only RB 318 327 tepoxalin tepoxalin NN 327 328 , , , 329 332 but but CC 333 336 not not RB 337 348 cyclosporin cyclosporin NN 348 349 , , , 350 360 suppresses suppress VBZ 361 369 NF-kappa NF-kappa NNP 370 371 B B NNP 372 382 activation activation NN 382 383 . . . 384 388 Here here RB 389 391 we we PRP 392 398 report report VBP 399 403 that that IN 404 413 tepoxalin tepoxalin NN 414 425 selectively selectively RB 426 434 inhibits inhibit VBZ 435 448 intercellular intercellular JJ 449 457 adhesion adhesion NN 458 468 molecule-1 molecule-1 NN 469 470 ( ( ( 470 476 ICAM-1 ICAM-1 NNP 476 477 , , , 478 489 CD54)/MAC-1 CD54)/MAC-1 NNP 490 491 ( ( ( 491 501 CD11b/CD18 cd11b/cd18 NN 501 502 ) ) ) 503 512 dependent dependent JJ 513 521 adhesion adhesion NN 522 524 of of IN 525 542 polymorphonuclear polymorphonuclear JJ 543 548 cells cell NNS 549 551 to to TO 552 556 IL-1 il-1 NN 557 566 activated activate VBN 567 572 human human JJ 573 582 umbilical umbilical JJ 583 587 vein vein NN 588 599 endothelial endothelial JJ 600 605 cells cell NNS 605 606 . . . 607 610 The the DT 611 620 mechanism mechanism NN 621 623 of of IN 624 634 inhibition inhibition NN 635 637 is be VBZ 638 645 related related JJ 646 648 to to TO 649 652 the the DT 653 660 surface surface NN 661 671 expression expression NN 672 674 of of IN 675 682 several several JJ 683 687 cell cell NN 688 696 adhesion adhesion NN 697 706 molecules molecule NNS 706 707 . . . 708 712 Flow Flow NNP 713 722 cytometry cytometry NN 723 731 analyses analysis NNS 732 734 on on IN 735 743 cultured culture VBN 744 749 cells cell NNS 750 754 that that WDT 755 759 were be VBD 760 767 treated treat VBN 768 772 with with IN 773 782 tepoxalin tepoxalin NN 783 785 or or CC 786 795 antisense antisense JJ 796 812 oligonucleotides oligonucleotide NNS 813 815 to to TO 816 819 the the DT 820 827 P65/p50 p65/p50 NN 828 835 subunit subunit NN 836 838 of of IN 839 847 NF-kappa NF-kappa NNP 848 849 B B NNP 849 850 , , , 851 854 and and CC 855 859 then then RB 860 870 stimulated stimulate VBN 871 875 with with IN 876 879 PMA PMA NNP 879 880 , , , 881 889 revealed reveal VBD 890 891 a a DT 892 899 reduced reduce VBN 900 910 expression expression NN 911 913 of of IN 914 924 CD11b/CD18 cd11b/cd18 NN 925 927 on on IN 928 937 monocytic monocytic JJ 938 942 HL60 hl60 NN 943 948 cells cell NNS 948 949 , , , 950 953 and and CC 954 965 endothelial endothelial JJ 966 974 adhesion adhesion NN 975 985 molecule-1 molecule-1 NN 986 987 ( ( ( 987 992 CD62E CD62E NNP 992 993 ) ) ) 994 997 and and CC 998 1006 vascular vascular JJ 1007 1015 adhesion adhesion NN 1016 1026 molecule-1 molecule-1 NN 1027 1028 ( ( ( 1028 1033 CD106 CD106 NNP 1033 1034 ) ) ) 1035 1037 on on IN 1038 1043 human human JJ 1044 1053 umbilical umbilical JJ 1054 1058 vein vein NN 1059 1070 endothelial endothelial JJ 1071 1076 cells cell NNS 1076 1077 . . . 1078 1088 Expression expression NN 1089 1091 of of IN 1092 1097 other other JJ 1098 1106 adhesion adhesion NN 1107 1116 molecules molecule NNS 1117 1121 such such JJ 1122 1124 as as IN 1125 1135 lymphocyte lymphocyte NN 1136 1144 function function NN 1145 1165 associated-antigen-1 associated-antigen-1 NN 1166 1167 ( ( ( 1167 1177 CD11a/CD18 cd11a/cd18 NN 1177 1178 ) ) ) 1179 1182 and and CC 1183 1187 CD54 CD54 NNP 1188 1192 were be VBD 1193 1203 unaffected unaffected JJ 1203 1204 . . . 1205 1214 Tepoxalin Tepoxalin NNP 1215 1219 also also RB 1220 1229 inhibited inhibit VBD 1230 1233 the the DT 1234 1243 secretion secretion NN 1244 1246 of of IN 1247 1248 a a DT 1249 1257 NF-kappa NF-kappa NNP 1258 1259 B B NNP 1260 1269 regulated regulated JJ 1270 1279 chemokine chemokine NN 1279 1280 , , , 1281 1285 IL-8 IL-8 NNP 1285 1286 , , , 1287 1288 a a DT 1289 1294 known known JJ 1295 1302 inducer inducer NN 1303 1305 of of IN 1306 1316 CD11b/CD18 cd11b/cd18 NN 1317 1327 expression expression NN 1327 1328 . . . 1329 1333 Thus thus RB 1334 1337 the the DT 1338 1349 suppression suppression NN 1350 1352 of of IN 1353 1363 CD11b/CD18 cd11b/cd18 NN 1364 1374 expression expression NN 1375 1377 by by IN 1378 1387 tepoxalin tepoxalin NN 1388 1391 may may MD 1392 1399 involve involve VB 1400 1404 IL-8 il-8 NN 1404 1405 . . . 1406 1409 Our our PRP$ 1410 1417 results result NNS 1418 1425 suggest suggest VBP 1426 1430 that that IN 1431 1433 by by IN 1434 1444 inhibiting inhibit VBG 1445 1453 NF-kappa NF-kappa NNP 1454 1455 B B NNP 1456 1466 activation activation NN 1466 1467 , , , 1468 1475 surface surface NN 1476 1486 expression expression NN 1487 1489 of of IN 1490 1497 several several JJ 1498 1506 adhesion adhesion NN 1507 1516 molecules molecule NNS 1517 1520 can can MD 1521 1523 be be VB 1524 1533 modulated modulate VBN 1534 1537 and and CC 1538 1542 that that IN 1543 1552 tepoxalin tepoxalin NN 1553 1556 may may MD 1557 1559 be be VB 1560 1566 useful useful JJ 1567 1569 in in IN 1570 1578 treating treat VBG 1579 1587 selected select VBN 1588 1596 adhesion adhesion NN 1597 1605 mediated mediated JJ 1606 1612 events event NNS 1613 1617 such such JJ 1618 1620 as as IN 1621 1630 leukocyte leukocyte NN 1631 1640 migration migration NN 1641 1643 or or CC 1644 1659 atherosclerotic atherosclerotic JJ 1660 1666 plaque plaque NN 1667 1676 formation formation NN 1676 1677 . . .